Theseus Pharmaceuticals to Participate Virtually in Needham Healthcare Conference

Rhea-AI Summary

Theseus Pharmaceuticals (NASDAQ: THRX), a clinical-stage biopharmaceutical company focusing on cancer treatments, announced participation in the 21st Annual Needham Virtual Healthcare Conference from April 11-14, 2022. The company's presentation is scheduled for April 13, 2022, at 12:45 PM ET, with a live webcast available on their investor relations website. Additionally, management will engage in one-on-one investor meetings throughout the conference. Theseus aims to combat cancer resistance through innovative therapies, including its lead candidate, THE-630, targeting advanced gastrointestinal stromal tumors.

CAMBRIDGE, Mass., April 5, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that it will participate in the 21^st Annual Needham Virtual Healthcare Conference, taking place April 11-14, 2022.

Presentation Details:
Event: 21^st Annual Needham Virtual Healthcare Conference
Date / Time: Wednesday, April 13^th, 2022, at 12:45pm ET
Format: Presentation

A live webcast will be available in the Events section of the company's investor relations website at ir.theseusrx.com and archived for 30 days following the presentation.

Management will also be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Theseus management team should contact their Needham representative.

About Theseus Pharmaceuticals, Inc.
Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target all known classes of cancer-causing and resistance mutations that lead to variants in a particular protein in a given type of cancer. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC). For more information, visit www.theseusrx.com.

Media Contact
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com

Investor Contact
Christen Baglaneas
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com

View original content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-participate-virtually-in-needham-healthcare-conference-301517224.html

SOURCE Theseus Pharmaceuticals

FAQ

What is the date of the 21st Annual Needham Virtual Healthcare Conference for Theseus Pharmaceuticals?

The conference will take place from April 11-14, 2022, with Theseus presenting on April 13, 2022.

How can I access the webcast for Theseus Pharmaceuticals' presentation at the Needham Conference?

The live webcast will be available in the Events section of the Theseus investor relations website.

What is the main focus of Theseus Pharmaceuticals as a company?

Theseus Pharmaceuticals focuses on developing transformative targeted therapies to improve the lives of cancer patients.

What is the lead product candidate of Theseus Pharmaceuticals?

The lead product candidate is THE-630, a pan-variant KIT inhibitor for advanced gastrointestinal stromal tumors.

Who should I contact for investor meetings with Theseus Pharmaceuticals during the conference?

Interested investors should contact their Needham representative to schedule a meeting with Theseus management.